MYCN and Mobius syndrome: Few therapeutic options exist for treating group 4-MBs; for tumors that express MYCN and CDK6 amplification, bromodomain inhibitors and cyclin-dependent kinase (CDK) inhibitors along with MYC-destabilizing Aurora kinase A inhibitors may be preferred [23,24].